Leerink Partnrs Has Pessimistic View of Hologic Q3 Earnings

Hologic, Inc. (NASDAQ:HOLX) – Analysts at Leerink Partnrs cut their Q3 2025 earnings per share estimates for shares of Hologic in a note issued to investors on Thursday, February 6th. Leerink Partnrs analyst P. Souda now forecasts that the medical equipment provider will post earnings of $1.10 per share for the quarter, down from their previous estimate of $1.12. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Leerink Partnrs also issued estimates for Hologic’s FY2025 earnings at $4.27 EPS, Q1 2026 earnings at $1.14 EPS, Q2 2026 earnings at $1.14 EPS, Q3 2026 earnings at $1.16 EPS, Q4 2026 earnings at $1.17 EPS, FY2026 earnings at $4.60 EPS and FY2027 earnings at $4.88 EPS.

HOLX has been the subject of several other research reports. Leerink Partners lowered shares of Hologic from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $80.00 to $75.00 in a research report on Thursday. Mizuho dropped their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th. BNP Paribas upgraded Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Evercore ISI lowered their price target on Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research report on Thursday. Finally, Royal Bank of Canada cut their price objective on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a report on Thursday. Ten research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Hologic has an average rating of “Moderate Buy” and an average target price of $85.77.

Hologic Trading Down 1.3 %

NASDAQ HOLX opened at $64.58 on Friday. The company has a 50-day moving average of $72.33 and a 200-day moving average of $77.76. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. Hologic has a 12 month low of $63.88 and a 12 month high of $84.67. The company has a market cap of $14.58 billion, a P/E ratio of 19.39, a P/E/G ratio of 2.35 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%.

Insider Activity

In other news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.88% of the company’s stock.

Institutional Investors Weigh In On Hologic

A number of hedge funds have recently bought and sold shares of HOLX. Prentiss Smith & Co. Inc. raised its position in shares of Hologic by 0.3% in the 3rd quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock valued at $3,967,000 after purchasing an additional 130 shares in the last quarter. Covestor Ltd raised its holdings in Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 133 shares in the last quarter. First Horizon Advisors Inc. grew its holdings in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares in the last quarter. Brooklyn Investment Group increased its position in shares of Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock worth $82,000 after purchasing an additional 145 shares during the last quarter. Finally, Empirical Finance LLC raised its stake in shares of Hologic by 1.8% in the 3rd quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock valued at $690,000 after purchasing an additional 147 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.